 | Up a level |
Zaman, K; Thürlimann, B; Huober, J; Schönenberger, A; Pagani, O; Lüthi, J; Simcock, M; Giobbie-Hurder, A; Berthod, G; Genton, C; Brauchli, P; Aebi, S (2012). Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07). Annals of oncology, 23(6), pp. 1474-1481. Oxford University Press 10.1093/annonc/mdr448
Rochlitz, C; Ruhstaller, T; Lerch, S; Spirig, C; Huober, J; Suter, T; Bühlmann, M; Fehr, M; Schönenberger, A; von Moos, R; Winterhalder, R; Rauch, D; Müller, A; Mannhart-Harms, M; Herrmann, R; Cliffe, B; Mayer, M; Zaman, K; Swiss Group for Clinical Cancer Research, (SAKK) (2011). Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06). Annals of oncology, 22(1), pp. 80-5. Oxford: Oxford University Press 10.1093/annonc/mdq319
